Oral Radiation Nuclear Decorporation Agents

口服辐射核修饰剂

• 批准号: 8534618
• 负责人: MICHAEL JAY
• 金额: $ 192.56万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8534618
• 关键词: Advanced Development; Calcium; Chelating Agents; Complex; Contracts; Enhancers; Excision; Investigational New Drug Application; Metabolic Clearance Rate; National Institute of Allergy and Infectious Disease; Nebulizer; Nuclear; Oral; Pentetic Acid; Plasma; Plutonium; Radiation; Radioactive; Radioisotopes; Research Personnel; Staging; Zinc; absorption; diethylenetriaminepentaacetate; uptake

The removal of certain internal radioactive contaminants can be accomplished by administering chelating agents that can preferentially complex with radionuclides in the body and increase their rate of clearance, thereby decreasing radiation exposure. Pentetate (diethylenetriaminepentaacetate) calcium trisodium (Ca-DTPA) and pentetate (diethylenetriaminepentaacetate) zinc trisodium (Zn-DTPA) have been shown to be effective in treating internal contamination with radionuclides such as plutonium, americium, or curium. However, because DTPA must be given intravenously or by nebulizer, it is not useful in a mass casualty situation. This Contract advances the development of oral forms of Ca-DTPA and Zn-DTPA that are more suitable for a mass casualty situation.

某些内部放射性污染物的清除可以通过使用能够优先与体内放射性核素形成络合物并增加其清除率的螯合剂来实现，从而减少辐射暴露。已证明五(二乙三胺五乙酸钙)钙三钠(Ca-DTPA)和五(二乙烯三胺五醋酸锌)锌三钠(锌-DTPA)在处理钚、汞或钚等放射性核素的内部污染方面是有效的。然而，由于DTPA必须静脉给药或通过雾化吸入，所以在大规模伤亡的情况下不起作用。这份合同促进了更适合于大规模伤亡情况的口服型Ca-DTPA和Zn-DTPA的开发。